Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Total Current Liabilities (2020 - 2025)

Maxcyte (MXCT) has disclosed Total Current Liabilities for 6 consecutive years, with $16.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities fell 8.62% to $16.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $16.1 million, a 8.62% decrease, with the full-year FY2024 number at $15.8 million, down 11.65% from a year prior.
  • Total Current Liabilities was $16.1 million for Q3 2025 at Maxcyte, up from $11.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $18.1 million in Q2 2022 to a low of $11.6 million in Q2 2025.
  • A 5-year average of $15.0 million and a median of $15.6 million in 2021 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 44.46% in 2022, then fell 27.08% in 2023.
  • Maxcyte's Total Current Liabilities stood at $15.6 million in 2021, then dropped by 1.22% to $15.4 million in 2022, then grew by 15.74% to $17.9 million in 2023, then fell by 11.65% to $15.8 million in 2024, then increased by 2.07% to $16.1 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Total Current Liabilities are $16.1 million (Q3 2025), $11.6 million (Q2 2025), and $12.7 million (Q1 2025).